Hossein Borghaei

Fox Chase Cancer Center

Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

h-index64

i10-index178

Publications515

Citations30,789

Grants

11 total · 2 active

NIH #5P30CA006927-57

Protocol Review and Monitoring System

Active

Amount: $204K
Period: 1997-07-01 → 2030-04-30
PIs: 1
Est. capacity / PI: ~0 students

Awarded at RESEARCH INST OF FOX CHASE CAN CTR

NIH #2P30CA006927-56A1

Protocol Review and Monitoring System

Active

Amount: $201K
Period: 1997-07-01 → 2030-04-30
PIs: 1
Est. capacity / PI: ~0 students

Awarded at RESEARCH INST OF FOX CHASE CAN CTR

NIH #5P30CA006927-55

Protocol Review and Monitoring System

Amount: $135K
Period: 1997-07-01 → 2024-12-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at RESEARCH INST OF FOX CHASE CAN CTR

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0033

PageRank within Pulmonary and Respiratory Medicine co-authorship network

Explore collaboration map

Admission Signals

New paper: Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab–Based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer (Clinical Cancer Research)2026-06-26
New preprint: Mitochondrial ACSS1 links acetate metabolism to pyrimidine biosynthesis in nutrient-stressed B-cell lymphomas2025-09-03
New NIH award: $204K — Protocol Review and Monitoring System1997-07-01
New NIH award: $201K — Protocol Review and Monitoring System1997-07-01

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0002-2577-4454

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 38

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab–Based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
Clinical Cancer Research · 2026-06-26
Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors
JCO Precision Oncology · 2026-06-01
A phase 1, first-in-human, open-label, dose-escalation and -expansion study of gamitrinib, a first-in-class, mitochondria-directed inhibitor of the molecular chaperone heat shock protein-90 (Hsp90) in patients with advanced cancer.
Journal of Clinical Oncology · 2026-05-28
Biomarker-Directed Precision Medicine for Lung Cancer Control
2025-11-13
Neoadjuvant Chemo-Immunotherapy for Surgically Resectable Non-Small Cell Lung Cancer: Balancing Promise and Pitfalls
Clinical Lung Cancer · 2025-11-08 · 2 citations
MA11.04 Safety of Lurbinectedin + Atezolizumab as 1L Maintenance Treatment in ES-SCLC: Results From the Phase 3 IMforte Study
Journal of Thoracic Oncology · 2025-10-01
Confidence in patient-provider consideration of immunotherapy in a congested landscape.
JCO Oncology Practice · 2025-10-01
Mitochondrial ACSS1 links acetate metabolism to pyrimidine biosynthesis in nutrient-stressed B-cell lymphomasPreprint
Cancer Letters · 2025-09-03
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
Nature Communications · 2025-08-19 · 9 citations
Data from Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non–Small Cell Lung Cancer: A Lung-MAP Study
2025-08-14
Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non–Small Cell Lung Cancer: A Lung-MAP Study
Clinical Cancer Research · 2025-06-04 · 1 citations
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
Journal of Thoracic Oncology · 2025-06-03 · 4 citations
S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent <i>KRAS</i> G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).
Journal of Clinical Oncology · 2025-05-28 · 2 citations
Optimizing tarlatamab therapy for relapsed small cell lung cancer: Biomarker identification and addressing treatment delivery disparity.
Journal of Clinical Oncology · 2025-05-28
Characterization of histology-dependent immunobiological differences in metastatic NSCLC: Implications for treatment with PD-1 and LAG-3 inhibitors.
Journal of Clinical Oncology · 2025-05-28
Clinical outcomes and characterization of HER2 alterations in non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology · 2025-05-28
Integrated Molecular and Clinical Characterization of Pulmonary Large Cell Neuroendocrine CarcinomaPreprint
Research Square · 2025-05-16
Abstract 3377: The impact of gender and age on real-world progression-free survival (rwPFS) in patients without a smoking history with NSCLC treated with checkpoint inhibitors
Cancer Research · 2025-04-21
Prevalence and molecular correlates of acquired <i>EGFR</i> resistance mutations in non-small cell lung cancer (NSCLC)
Expert Review of Anticancer Therapy · 2025-04-16 · 1 citations
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial
Advances in Therapy · 2025-03-03 · 11 citations

Open author page on OpenAlex →